To Evaluate Hallux Terbinafine Subungual Gel (HSG) in the Treatment of Onychomycosis
Status:
Not yet recruiting
Trial end date:
2023-09-30
Target enrollment:
Participant gender:
Summary
The key objective is to establish the efficacy, safety, tolerability, and pharmacokinetics of
investigational drug Hallux Terbinafine Subungual Gel (HSG) administered over 44 weeks to
patients with distal-lateral subungual onychomycosis (DLSO).